我的生活+的主要目标之一是帮助人们预防新的HIV和其他STI,丙型肝炎和结核病病历的产生。

该应用程序有助于建立医生和HIV感染者之间的匿名沟通。 它可以让您创建简单易行的服药时间表,并设置隐藏和个性化的提醒。

返回
12 九月 2017, 12:30
3546

Achillion Pharmaceuticals and J&J Were Slightly Down in Premarket Trading After the Discontinuation of Further Hepatitis C Treatment Investigation Was Announced

Achillion Pharmaceuticals and J&J Were Slightly Down in Premarket Trading After the Discontinuation of Further Hepatitis C Treatment Investigation Was Announced - 图片 1

Johnson & Johnson with Achillion Pharmaceuticals were down slightly at more than 20 percent in premarket trading after the announcement of Janssen Sciences Ireland about the discontinuation of further development of hepatitis C treatment investigation. The Janssen authorities comment on that it was a strategic decision because of the number of brand new therapy for hepatitis C, and the number increases rapidly.

"Going forward, our hepatitis R&D efforts will focus on chronic hepatitis B, where a high unmet medical need still exists," comment on  Lawrence Blatt, global therapeutic area head, infectious disease therapeutics, Janssen.

作者: Liliya Ten

在社交媒体上分享